EMA Reciprocity for U.S. Drugs

FDA and Europe’s EMA agree on 90–95% of new drug approvals, and in all eight recent cases where EMA approved and FDA initially balked, FDA later reversed. Use this convergence to presume safety for EMA‑cleared drugs and give them an accelerated U.S. pathway. That would increase competition and access without importing foreign price controls. — Reciprocity would reframe drug affordability as a regulatory‑coordination problem rather than a price‑mandate fight, with knock‑on effects for innovation and patient access.